25-gauge PPV: safe and effective

Article

25-gauge pars plana vitrectomy (PPV) appears to be safe and effective for the treatment of epiretinal membranes.

25-gauge pars plana vitrectomy (PPV) appears to be safe and effective for the treatment of epiretinal membranes, according to a report published online ahead of print by Der Ophthalmologe.

Albrecht Lommatzsch and colleagues from St. Franziskus Hospital MÜnster, Germany investigated 625 eyes from 620 patients who were operated on using the 25-gauge technique between 2002 and 2006.

The epiretinal membranes were successfully removed in all patients and 329 eyes were analyzed with long-term follow-up over 3.1 years. The mean improvement in visual acuity (VA) before and after surgery was -09.41 in logMAR and normal intraocular pressure (IOP) was observed in all patients one week postoperatively. In nine patients with postoperative hypotony and choroidal detachment, an additional suture was required and seven patients developed a retinal detachment. No patients developed endophthalmitis during the follow-up period.

The 25-gauge PPV technique, according to the researchers, appears to be both safe and effective.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.